^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IL7R (Interleukin 7 Receptor)

    i
    Other names: IL7R, Interleukin 7 Receptor, Interleukin-7 Receptor Subunit Alpha, IL-7 Receptor Subunit Alpha, L-7R Subunit Alpha, CD127 Antigen, IL-7R-Alpha, Interleukin 7 Receptor Isoform H5-6, Interleukin 7 Receptor Alpha Chain, CDW127, CDw127, IL-7RA, CD127, IL7RA, ILRA
    4d
    Investigating the role of inflammatory bowel disease-associated gene expression in oral cancer using single-cell RNA sequencing. (PubMed, Clin Transl Oncol)
    This study highlights the cellular heterogeneity and distinct gene expression programs inoral cancer, emphasizing the relevance of IBD-associated genes. The association between NFKBIA expression and chemokine-mediated signaling provides insights that may contribute to the development of personalized therapeutic strategies for IBD-related mechanisms in oral cancer.
    Journal
    |
    IL7R (Interleukin 7 Receptor) • ATG5 (Autophagy Related 5) • NFKBIA (NFKB Inhibitor Alpha 2) • RB1CC1 (RB1 Inducible Coiled-Coil 1)
    7d
    Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancer. (PubMed, J Transl Med)
    PIE represents a clinically relevant, transcriptome-based predictive model for evaluating the benefit of ICI treatment in advanced NSCLC. With further prospective validation, PIE may facilitate personalized patient selection and guide the development of novel strategies to overcome primary resistance.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IL7R (Interleukin 7 Receptor) • NCAM1 (Neural cell adhesion molecule 1) • KRT14 (Keratin 14) • SLC31A2 (Solute Carrier Family 31 Member 2) • SLC4A1 (Solute Carrier Family 4 Member 1)
    11d
    IL7R remodels immunosuppression tumor microenvironment and promotes macrophage polarization by regulating NF-κB/CXCL1 axis in ovarian cancer. (PubMed, Cell Death Dis)
    These polarized macrophages further enhance tumor cell proliferation and invasion, thereby forming a tumor-immune feedback loop. In conclusion, this study clarifies how IL7R signaling mediates crosstalk between ovarian cancer cells and macrophages to maintain the homeostasis of the immunosuppressive tumor microenvironment (TME).
    Journal
    |
    IL7R (Interleukin 7 Receptor) • IL10 (Interleukin 10) • ARG1 (Arginase 1) • IL7 (Interleukin 7) • MRC1 (Mannose Receptor C-Type 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    20d
    METTL14 Regulates the Expression of Genes Related to Interferon, Interleukin and MHC Class I in Nasopharyngeal Carcinoma Cells. (PubMed, Cancer Med)
    These findings demonstrate, for the first time, that METTL14 modulates the expression of genes related to TNF, IFN, IL, and MHC class I in NPC, proposing a novel role for METTL14 in linking inflammation with cancer, a function that has not been fully elucidated.
    Journal
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL7R (Interleukin 7 Receptor) • TNFRSF9 (TNF Receptor Superfamily Member 9) • HLA-B (Major Histocompatibility Complex, Class I, B) • IL32 (Interleukin 32) • CD40LG (CD40 ligand) • IFI16 (Interferon Gamma Inducible Protein 16) • IL1B (Interleukin 1, beta) • IL7 (Interleukin 7) • PSMA2 (Proteasome 20S Subunit Alpha 2) • PSMC6 (Proteasome 26S Subunit, ATPase 6) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • HLA-C (Major Histocompatibility Complex, Class I, C) • METTL14 (Methyltransferase 14) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    23d
    Safety and efficacy of the therapy with CD4 + CD25highCD127-T regulatory cells: When paediatric patient becomes adult. (PubMed, Diabetes Obes Metab)
    We confirmed the long-term safety and efficacy of the therapy. Due to the superior efficacy profile, the combined treatment with Tregs and antiCD20 antibody should be considered as a routine therapy for recent-onset type 1 diabetes patients.
    Journal
    |
    CD4 (CD4 Molecule) • IL7R (Interleukin 7 Receptor)
    25d
    De Novo Design of Peptide Masks Enables Rapid Generation of Conditionally-Active Miniprotein Binders. (PubMed, J Am Chem Soc)
    Additionally, by chemically conjugating a photocleavable linker, we created a light-responsive version of the masked binder, enabling external control with comparable efficiency to protease-sensitive designs. This work establishes a generalizable, rapid, and efficient platform for designing cleavable peptide masks from scratch, paving the way for conditionally active protein therapeutics responsive to endogenous or exogenous stimuli.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • FGFR2 (Fibroblast growth factor receptor 2) • IL7R (Interleukin 7 Receptor)
    1m
    Distinct functional heterogeneity of TP53 R175 mutations in platinum-resistant ovarian cancer: unveiling molecular mechanisms and therapeutic targets. (PubMed, Cell Death Dis)
    Moreover, CHD1 knockdown or pharmacological inhibition of IL7R synergistically enhanced platinum sensitivity, suggesting promising combination therapies specifically targeting the R175G mutation. The findings revealed that p53 mutations at the same residue exhibited distinct functional properties and relied on unique cofactors, offering valuable insights for precision therapy in OC.
    Journal • Platinum resistant
    |
    TP53 (Tumor protein P53) • IL7R (Interleukin 7 Receptor) • CHD1 (Chromodomain Helicase DNA Binding Protein 1) • ARG1 (Arginase 1)
    |
    TP53 mutation
    1m
    Application value of bone metabolism and immune cell indicators in screening for tumor bone metastasis: a retrospective study. (PubMed, Am J Cancer Res)
    The combined assessment of bone metabolism and immune indicators provides high clinical value for screening tumor bone metastasis.
    Retrospective data • Journal
    |
    CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL7R (Interleukin 7 Receptor) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    1m
    Multi-compartment immune cell profiling highlights the prognostic relevance of CD127+ CD8+ T cells for patients with high-grade serous ovarian cancer. (PubMed, Front Immunol)
    In particular, significant positive correlations of CD127+ CD8+ T cells among all three compartments were shown. Our results provide evidence that a higher proportion of peripheral CD127+ CD8+ T cells, which are memory T cells with low granzyme B production, was a prognostic biomarker for unfavorable progression-free survival of high-grade OC patients, independent of FIGO stage III/IV or residual tumor after surgery.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL7R (Interleukin 7 Receptor) • GZMB (Granzyme B) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1) • NKG2D (killer cell lectin like receptor K1)
    1m
    Transcriptome biomarkers of colon cancer liver metastasis response to neoadjuvant triplet chemotherapy: a case series. (PubMed, J Circ Biomark)
    The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) may be considered an effective option in the neoadjuvant setting for metastatic colon cancer (mCRC). Data obtained indicate transcriptional discordance between the primary tumors and liver metastases during neoadjuvant FOLFOXIRI, with the pattern of DEGs involved in their response being distinct. The EPS8L2 transcript could be regarded as a candidate biomarker of liver complete response; however, prognostic conclusions cannot be drawn from this cohort.
    Journal
    |
    IL7R (Interleukin 7 Receptor) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • SERPINE1 (Serpin Family E Member 1) • IL1RN (Interleukin 1 receptor antagonist) • NAMPT (Nicotinamide Phosphoribosyltransferase) • PER1 (Period Circadian Clock 1) • TAGLN (Transgelin) • ZBTB16 (Zinc Finger And BTB Domain Containing 16) • ATF3 (Activating Transcription Factor 3) • CTGF (Connective tissue growth factor) • DUSP1 (Dual Specificity Phosphatase 1) • GADD45B (Growth Arrest And DNA Damage Inducible Beta) • ISG20 (Interferon Stimulated Exonuclease Gene 20) • TSC22D3 (TSC22 Domain Family Member 3)
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    1m
    High-dimensional spectral cytometry identifies follicular regulatory CD8+ T cells in diffuse large B-cell lymphoma. (PubMed, Clin Transl Immunology)
    Our study highlights the utility of high-dimensional computational cytometry in elucidating T-cell subpopulations, including an increased frequency of CD8+ follicular regulatory T cells and their communication patterns within the DLBCL TME. This unbiased approach sheds light on novel cellular mechanisms in DLBCL, uncovering potential targets and biomarkers for immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2RA (Interleukin 2 receptor, alpha) • IL7R (Interleukin 7 Receptor) • ICOS (Inducible T Cell Costimulator) • CCR7 (Chemokine (C-C motif) receptor 7) • FAS (Fas cell surface death receptor) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    1m
    Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma. (PubMed, Immunity)
    Metabolic flux modeling predicted enhanced microbial production of butyrate in melanoma patients with complete therapeutic responses to immune checkpoint blockade (ICB), and butyrate induced transcriptional features of ICB responsiveness in CD8+ T cells. Our findings suggest a critical role for metabolite production shared across several microbiota species in the preservation of stem-like tumor-specific CD8+ T cells.
    Journal
    |
    IL7R (Interleukin 7 Receptor)